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background: Sphericity index (SI) is a well-known predictor for the geometrical change of the left ventricle (LV) and long-term survival. We sought 
to evaluate how baseline SI affected clinical outcome and was altered after coronary artery bypass graft surgery (CABG) with or without surgical 
ventricular reconstruction (SVR) in ischemic cardiomyopathy patients enrolled in the SVR arm of the Surgical Treatment for Ischemic Heart Failure 
(STICH) trial.
Methods: Among the patients in the STICH SVR arm, we evaluated 546 patients (255 randomized to CABG alone and 291 to CABG+SVR) whose 
baseline SI values were available. SI was calculated from LV short-axis dimension divided by LV long-axis dimension measured at end-diastole. We 
used paired t-tests to compare changes in echocardiographic variables from baseline to 4 months and from 4 months to 2 years within treatment 
group and two-sample t-tests to compare differences in baseline variables and changes over time by treatment. We evaluated associations of 
baseline SI and treatment with all-cause mortality using Cox proportional hazards models adjusted for age, sex, and body mass index.
results: SI was not significantly different between treatment groups at baseline (P=0.42). After 4 months, SI significantly increased in the SVR 
group (0.69±0.10 to 0.77±0.12) compared to CABG alone (0.68±0.08 to 0.66±0.09, P<0.001) and remained unchanged at 2-year follow-up. 
LV end-systolic volume was reduced and ejection fraction was increased in the SVR group compared to the CABG alone (P=0.002 and P=0.012 
respectively). However, LV diastolic filling pressure and grade of mitral regurgitation improved only in the CABG alone group, which was not evident 
in the SVR group. Higher baseline SI was associated with worse survival after surgery (HR 1.21, 95% CI 1.02−1.43, P=0.026). Survival was not 
significantly different by treatment strategy (HR of CABG+SVR versus CABG=0.99, 95% CI =0.72−1.35, P=0.94).
conclusions: Although SVR was designed to improve LV geometry, SI worsened despite improved LV ejection fraction and smaller LV volume. 
Survival was significantly better in patients with lower SI at baseline regardless of treatment strategy.
